Creative Medical achieves second WHO INN milestone

Creative Medical (CELZ) Technology Holdings announced the achievement of its second International Nonproprietary Name milestone with the World Health Organization, marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide. The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell immunotherapy program, in Proposed INN List 134, following expert review during the 80th WHO INN Consultation. As part of the standard WHO process, the name is now entering the formal objection period prior to final confirmation.